| Item Type | Name |
|
Concept
|
Colorectal Neoplasms
|
|
Academic Article
|
Adjuvant therapy for colorectal cancer.
|
|
Academic Article
|
Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer.
|
|
Academic Article
|
Immunotherapy for colorectal cancer.
|
|
Academic Article
|
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
|
|
Academic Article
|
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
|
|
Academic Article
|
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
|
|
Academic Article
|
Pharmacology and clinical status of capecitabine.
|
|
Academic Article
|
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
|
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
|
Academic Article
|
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
|
|
Academic Article
|
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
|
|
Academic Article
|
Oral fluoropyrimidine treatment of colorectal cancer.
|
|
Academic Article
|
Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs.
|
|
Academic Article
|
Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation.
|
|
Academic Article
|
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
|
|
Academic Article
|
Cetuximab in the treatment of colorectal cancer.
|
|
Academic Article
|
Is oral tegafur with leucovorin equivalent to intravenous 5-fluorouracil and leucovorin in colorectal cancer?
|
|
Academic Article
|
Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program.
|
|
Academic Article
|
First-line treatment options for patients with metastatic colorectal cancer.
|
|
Academic Article
|
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
|
|
Academic Article
|
A phase I study of intermittent infusion cladribine in patients with solid tumors.
|
|
Academic Article
|
Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer.
|
|
Academic Article
|
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
|
|
Academic Article
|
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
|
|
Academic Article
|
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
|
|
Academic Article
|
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
|
|
Academic Article
|
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
|
|
Academic Article
|
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
|
|
Academic Article
|
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.
|
|
Academic Article
|
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
|
|
Academic Article
|
Integrating biomarkers in colorectal cancer trials in the West and China.
|
|
Academic Article
|
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary.
|
|
Academic Article
|
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
|
|
Academic Article
|
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
|
Academic Article
|
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
|
|
Academic Article
|
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
|
Grant
|
CELLULAR PHARMACOLOGY OF THE STEREOISOMERS OF LEUCOVORIN
|
|
Academic Article
|
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
|